跳至主要内容
临床试验/NCT01773226
NCT01773226已完成不适用

A Prospective Single-Center Clinical Study of a Single Intra-Articular Injection of Autologous Protein Solution ("APS(TM)") in Patients With Osteoarthritis (OA) of the Knee

Zimmer Biomet1 个研究点 分布在 1 个国家目标入组 11 人开始时间: 2013年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
Zimmer Biomet
入组人数
11
试验地点
1
主要终点
Number of Adverse Events

研究概览

简要总结

This prospective single-center study will evaluate the safety and tolerability of a single dose of "APS(TM)" treated patients with OA of the knee who have failed conservative OA therapy. The study will also evaluate efficacy by assessing patient pain and functionality.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Eligibility Criteria:
  • •Male or female ≥40 years.
  • •Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions.
  • •A standing radiograph of the knee showing a Kellgren grade of 2 or 3
  • •Frequency of knee pain on most days over the last month.
  • •Diagnosis of unilateral knee OA
  • •Body mass index (BMI) ≤40 kg/m
  • •Failed conservative OA therapy.
  • •Signed an independent ethics committee (IEC)-approved informed consent form (ICF).
  • •Willingness to abstain from the use of topical pain therapies, intra-articular corticosteroids, and viscosupplementation during the study.
  • •Willingness to abstain from systemic pain medications except rescue medication.

排除标准

  • 未提供

研究组 & 干预措施

Autologous Protein Solution "APS(TM)"

Experimental

Patients who have been treated with a single, intra-articular injection.

干预措施: Autologous Protein Solution "APS(TM)" (Device)

结局指标

主要结局

Number of Adverse Events

时间窗: Up to 6 months post-injection

Safety and tolerability will be assessed from AEs and injection-site reactions, physical examinations, knee examinations, vital signs, ECGs, and clinical laboratory tests (hematology, coagulation, blood chemistry, and urinalysis) evaluated at baseline (pre-injection) and post-injection up to 6 months.

次要结局

  • Number of Patients Using Rescue Medication(Up to 6 months post-injection)
  • Pain Score(Baseline, Week 1, Week 2, and at Months 1, 3, and 6.)
  • Stiffness Score(Baseline, Week 1, Week 2, and at Months 1, 3, and 6.)
  • Physical Function Score(Baseline, Week 1, Week 2, and at Months 1, 3, and 6.)

研究者

发起方
Zimmer Biomet
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验